Adjuvant therapy can reduce the risk for distant and local recurrence and extend survival in patients with early breast cancer. In this virtual Roundtable, Drs Ann Partridge, Antonio Wolff, and Katie Reeder-Hayes discuss treatment considerations for patients with early breast cancer, focusing on recent advances and growing options in adjuvant therapy.
For many patients diagnosed with early-stage breast cancer, adjuvant therapy after surgery or radiotherapy can reduce the risk for distant and local recurrence and extend survival.
In this virtual Roundtable, Drs Ann Partridge, Antonio Wolff, and Katie Reeder-Hayes discuss recent advances in adjuvant therapy that could usher in new standards of care in early breast cancer.
First, the panelists review considerations of patient-centered care in the adjuvant setting.
They continue by discussing strategies for optimizing therapy on the basis of breast cancer subtype.
They then address reasons why patients stop their adjuvant therapy and what can be done to improve adherence.
The panelists conclude the discussion by examining how genetic and biomarker testing can be used to identify patients who are most likely to benefit from specific adjuvant therapies.
Ann H. Partridge, MD, MPH, has disclosed no relevant financial relationships.
Antonio C. Wolff, MD, has disclosed no relevant financial relationships.
Katie Reeder-Hayes, MD, MBA, MSc, has disclosed the following relevant financial relationships:
Received research grant from: Pfizer Medical Foundation